BioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BioLife Solutions, Inc. (NASDAQ:BLFS) has been assigned an average rating of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $32.00.

Several research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of BioLife Solutions in a research report on Monday, December 29th. Northland Securities set a $34.00 target price on shares of BioLife Solutions in a research note on Monday, January 5th. Finally, Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th.

BioLife Solutions Trading Down 1.4%

Shares of NASDAQ BLFS opened at $19.12 on Thursday. The stock has a fifty day simple moving average of $22.42 and a two-hundred day simple moving average of $24.71. BioLife Solutions has a 1-year low of $17.86 and a 1-year high of $29.62. The firm has a market cap of $923.50 million, a price-to-earnings ratio of -173.80 and a beta of 1.90.

Insider Buying and Selling

In other BioLife Solutions news, insider Karen A. Foster sold 96,923 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $20.15, for a total transaction of $1,952,998.45. Following the sale, the insider owned 113,742 shares of the company’s stock, valued at $2,291,901.30. The trade was a 46.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Troy Wichterman sold 990 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total value of $25,334.10. Following the sale, the chief financial officer owned 150,746 shares in the company, valued at approximately $3,857,590.14. This represents a 0.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 101,956 shares of company stock valued at $2,068,241 over the last quarter. 2.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC purchased a new position in BioLife Solutions during the 4th quarter valued at about $30,000. Kemnay Advisory Services Inc. purchased a new stake in shares of BioLife Solutions in the fourth quarter worth about $35,000. Hantz Financial Services Inc. lifted its holdings in shares of BioLife Solutions by 54.1% in the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 659 shares in the last quarter. Quarry LP boosted its position in shares of BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 713 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its position in shares of BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 441 shares during the period. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.